Nilotinib-Induced Thromboembolic Events: A Case Study
Zahra Kmira, Ben Yahya Noura, Guermazi Monia, Fathallah Neila, Atig Amira, Chembah Wafa, Thabet Maissa, Zaier Monia, Ben Youssef Yosra, Haifa Regaieg & Khelif Abderrahim · Journal of Advances in Biology & Biotechnology · 2025
Nilotinib has significantly improved the treatment of chronic myeloid leukemia (CML) by offering enhanced efficacy and tolerability. However, studies have revealed a concerning link between nilotinib and an increased risk of thromboembolic events, even compared to other tyrosine...
Open access
Research Article
10.9734/jabb/2025/v28i11912